Mounting evidence for a multiple sclerosis prodrome

  title={Mounting evidence for a multiple sclerosis prodrome},
  author={Ruth Ann Marrie},
  journal={Nature Reviews Neurology},
  • R. Marrie
  • Published 16 October 2019
  • Medicine
  • Nature Reviews Neurology
A new study provides direct biological evidence for a prodromal phase of multiple sclerosis (MS), with implications for studying disease aetiology and underscoring the limitations of therapies that solely target inflammation. The findings also suggest an opportunity to apply secondary prevention strategies at the very earliest stages of the disease. 
4 Citations

Topics from this paper

The multiple sclerosis prodrome
A better understanding of the MS prodrome could have profound clinical implications as it could enable earlier recognition of MS and earlier initiation of treatments that reduce relapse rates and long-term disability.
Gender-Related Differences in Prodromal Multiple Sclerosis Characteristics: A 7-Year Observation Study
This study aimed to compare a broad spectrum of prodromal signs and symptoms between males and females in the 7-year period before the definite diagnosis of MS in Poland, and shed more light on well-known differences in the epidemiological and clinical characteristics between sexes in multiple sclerosis.
Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?
A look over 18 months of SARS-CoV-2 pandemic from the perspective of MS is looked at, dissect neuroinflammatory and demyelinating mechanisms associated with COVID-19, and summarize pathophysiological crossroads between MS and Sars-Cov-2 infection.
Bipedal hopping as a new measure to detect subtle sensorimotor impairment in people with multiple sclerosis.
The biomechanics of bipedal hopping is outlined and its usefulness as a novel outcome measure for people with MS having mild disability is proposed and multiple variables measured can discern type of sensorimotor impairment to direct personalized rehabilitation programs.


Prodromal symptoms of multiple sclerosis in primary care
Early diagnosis and treatment initiation significantly influence long‐term disability outcome in multiple sclerosis (MS). We aimed at identifying prodromal symptoms of MS in primary care settings.
Preclinical disease activity in multiple sclerosis: A prospective study of cognitive performance prior to first symptom
To prospectively investigate potential signs of preclinical multiple sclerosis (MS) activity and when they are present prior to first symptom using data from a historical cohort.
Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study
More frequent use of health care in patients with multiple sclerosis than in controls in the 5 years before a first demyelinating event, according to health administrative data, suggests the existence of a measurable multiple sclerosis prodrome.
Five years before multiple sclerosis onset: Phenotyping the prodrome
P phenotyping the prodrome 5 years before clinical recognition of MS is feasible, and cases had more psychiatrist and urologist encounters and higher proportions of musculoskeletal, genito-urinary or hormonal-related prescriptions.
MDS research criteria for prodromal Parkinson's disease
  • D. Berg, R. Postuma, +17 authors G. Deuschl
  • Psychology, Medicine
    Movement disorders : official journal of the Movement Disorder Society
  • 2015
These criteria represent a first step in the formal delineation of early stages of PD and will require constant updating as more information becomes available.
Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event
Data provide supportive evidence that a meaningful number of RIS subjects evolve to a first clinical symptom, and an age <37 y, male sex, and spinal cord involvement appear to be the most important independent predictors of symptom onset.
Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis.
The levels of sNfL were increased 6 years before the clinical onset of multiple sclerosis, indicating that MS may have a prodromal phase lasting several years and that neuroaxonal damage occurs already during this phase.
Wiping Out CGRP: Potential Cardiovascular Risks.
The cerebro- and cardiovascular risks that might be associated with CGRP blockade are reviewed and which clinical and preclinical studies should be conducted to better assess the potential safety issues of this new promising class of drug.
Basic mechanisms of migraine and its acute treatment.
An updated analysis of the basic mechanisms involved in the pathophysiology of migraine and the various pharmacological approaches that have shown efficacy for the acute treatment of this disorder are provided.
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
There was not enough evidence to provide recommendations using the GRADE approach and recommendations relied on experts’ opinion, but monoclonal antibodies acting on the calcitonin gene-related peptide are new drugs which can be recommended for migraine prevention.